Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
Bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL) can be morphologically discordant from the primary tumor. Concordant BM infiltration has been shown associated with a poorer outcome in patients treated with CHOP. In order to evaluate tumor-related factors leading to BM involvement in DLBCL, we performed an integrated analysis of i) genomic profiles obtained with a high-density genome wide SNP-based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly treated with R-CHOP. BM infiltration was found in 27 of 133 (20%) cases; and it was concordant in 18/27 (67%) cases. Concordant infiltration, but not discordant, influenced negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and higher PD rates. No association with cell of origin was found between BM+ and BM- DLBCL. As compared with BM- cases, BM+ DLBCL showed absence of 7q gain.
Chigrinova
Ekaterina
E
Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
Mian
Michael
M
Scandurra
Marta
M
Greiner
Timothy C
TC
Chan
Wing C
WC
Vose
Julie M
JM
Inghirami
Giorgio
G
Chiappella
Annalisa
A
Baldini
Luca
L
Ponzoni
Maurilio
M
Ferreri
Andrés J M
AJ
Franceschetti
Silvia
S
Gaidano
Gianluca
G
Tucci
Alessandra
A
Facchetti
Fabio
F
Lazure
Thierry
T
Lambotte
Olivier
O
Montes-Moreno
Santiago
S
Piris
Miguel A
MA
Nomdedeu
Josep Fr
JF
Uccella
Silvia
S
Rancoita
Paola M V
PM
Kwee
Ivo
I
Zucca
Emanuele
E
Bertoni
Francesco
F
D001853:Bone Marrow / Q000473:pathology*; D002869:Chromosome Aberrations; D020869:Gene Expression Profiling; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis